Among the 89 rejection letters the Food and Drug Administration released last week detailing safety and effectiveness issues that prevented drugs from being approved was one of particular interest to ...

Aug 15 (Reuters) - Lykos Therapeutics will lay off 75% of its workforce, or about 100 employees, and founder Rick Doblin will leave the board, the company said on Thursday, days after the U.S. FDA ...

The CEO of Lykos Therapeutics will step down after the company's efforts to win a milestone approval for MDMA as a therapy aid were rejected by the Food and Drug Administration last month. Amy Emerson ...

The journal Psychopharmacology has retracted three research papers on MDMA-assisted therapy due to alleged unethical conduct at study site In 2015, an unlicensed therapist who was part of the trial ...

Lykos Therapeutics is restructuring after the FDA denied approval for MDMA-AT, reducing its workforce by 75% to focus on clinical development and FDA engagement. The FDA requested a third phase 3 ...

Lykos Therapeutics announced it would cut 75% of its staff as part of a reorganization on Thursday afternoon. This announcement came less than one week after the Food and Drug Administration rejected ...

SAN JOSE, Calif., Aug. 9, 2024 /PRNewswire/ -- Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, announced that the U.S. Food and Drug Administration ("FDA") has ...

FDA independent advisors have comprehensively voted against the use of Lykos Therapeutics’ therapy for post-traumatic stress disorder (PTSD) based on MDMA, also known as ecstasy, in a setback for the ...

MAPS Public Benefit Corp. said Friday it raised $100 million in an oversubscribed Series A round of financing as it works to win approval from the U.S. Food and Drug Administration to become the first ...